Tranexamic acid (TXA)

1000mg/10ml ampoules (IV)

Executive Summary

(Updated December 2022)

The antifibrinolytic agent tranexamic acid (TXA) is a synthetic lysin derivative that binds plasminogen and plasmin, blocking their interaction with fibrin (4). It is indicated extensively in the ED for a variety of bleeding scenarios.

  • The most validated usage is in patients with acute trauma with a suspected severe hemorrhage (1, 3, 5, 7, 12). Currently it is an established component of “damage control resuscitation” (3, 5, 9).

  • All-cause mortality reduction was proven by the game-changer CRASH-2 trial –a strong double-blind RCT that compared TXA versus a placebo in trauma, based on the uncertainty principle (attending physician not being sure if TXA was beneficial or not)(1)–. Afterwards other studies have documented improved survival rates (3, 7, 11).

  • Later on TXA was studied in acute traumatic brain injury (TBI). It was found to have a limited potential benefit in reducing head injury associated deaths in mild to moderate TBI (6). Nonetheless TXA was recently indicated and included for TBI in combat medical guidelines (8, 9).

Adult dose for trauma with risk of significant hemorrhage (1)

1gr in 10 min + 1gr in 8 hrs IV.

Adult dose

Adult dose for trauma with risk of significant haemorrhage (1)

  • 1gr in 10 min + 1gr in 8 hrs IV.

Patient selection

  • Undifferentiated Trauma; based on CRASH-2 criteria: “adult trauma patients with significant hemorrhage (systolic blood pressure <90 mm Hg or heart rate >110 beats per min, or both), or who were considered to be at risk of significant hemorrhage” (1).

  • Traumatic Brain Injury; based on CRASH-3 criteria: "adults with TBI who were within 3 h of injury, had a Glasgow Coma Scale (GCS) score of 12 or lower or any intracranial bleeding on CT scan" (6). Potential benefit in mild to moderate TBI (Glasgow Coma Scale 9 to 15).

  • Some experts initiate TXA if the ABC score is ≥2 (ABC Score for Massive Transfusion - MDCalc), when massive transfusion is likely required.

Best timing to administer TXA

  • Best time is early: <1 hour of injury.

  • TXA should be administered early within 3 hours from injury, with the most beneficial results when administered in the first hour (2).

About trauma-associated coagulopathy

From a physiopathological point of view, TXA should be administered when fibrinolytic activity is augmented, which can objectively be measured with viscoelastic assays like thromboelastography (TEG)(10). Interestingly, recent studies show that an early administration of TXA prevents development of a hyperfibrinolytic state which supports its usage not only in severely injured patients (7, 12, 13).


Remarkable compendiums and analyses of the trial can be found at The Bottom Line and at The NNT.


  1. CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5
    The Lancet (Open Access)

  2. CRASH-2 collaborators, Roberts I, Shakur H, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101.e11012. doi:10.1016/S0140-6736(11)60278-X

  3. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012;147(2):113-119. doi:10.1001/archsurg.2011.287

  4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th edition. McGraw Hill; 2017.

  5. Cap AP, Pidcoke HF, Spinella P, et al. Damage Control Resuscitation. Mil Med. 2018;183(suppl_2):36-43. doi:10.1093/milmed/usy112

  6. CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial [published correction appears in Lancet. 2019 Nov 9;394(10210):1712]. Lancet. 2019;394(10210):1713-1723. doi:10.1016/S0140-6736(19)32233-0

  7. Ageron FX, Gayet-Ageron A, Ker K, et al. Effect of tranexamic acid by baseline risk of death in acute bleeding patients: a meta-analysis of individual patient-level data from 28 333 patients. Br J Anaesth. 2020;124(6):676-683. doi:10.1016/j.bja.2020.01.020

  8. Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. doi:10.55460/ZWV3-5CBW

  9. Tactical Combat Casualty Care (TCCC) Guidelines for Medical Personnel 15 December 2021. J Spec Oper Med. 2022;22(1):11-17. doi:10.55460/ETZI-SI9T

  10. Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy [published correction appears in Nat Rev Dis Primers. 2022 Apr 22;8(1):25]. Nat Rev Dis Primers. 2021;7(1):30. Published 2021 Apr 29. doi:10.1038/s41572-021-00264-3

  11. Imach S, Wafaisade A, Lefering R, et al. The impact of prehospital tranexamic acid on mortality and transfusion requirements: match-pair analysis from the nationwide German TraumaRegister DGU®. Crit Care. 2021;25(1):277. Published 2021 Aug 4. doi:10.1186/s13054-021-03701-7

  12. Roberts I, Ageron FX. The role of tranexamic acid in trauma - a life-saving drug with proven benefit. Nat Rev Dis Primers. 2022;8(1):34. Published 2022 May 26. doi:10.1038/s41572-022-00367-5

  13. Rossetto A, Vulliamy P, Lee KM, Brohi K, Davenport R. Temporal Transitions in Fibrinolysis after Trauma: Adverse Outcome Is Principally Related to Late Hypofibrinolysis. Anesthesiology. 2022;136(1):148-161. doi:10.1097/ALN.0000000000004036


® 2023 EMDrugs. All rights reserved.


This website provides general information and discussion about medications, health, and related subjects. The words and other con­tent pro­vided in this website, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other legally accredited health care worker in the country that resides or is visiting.

Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations.

The views expressed on this blog and web­site have no rela­tion to those of any academic, hospital, practice or other insti­tu­tion with which the authors are affiliated.

For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.

EMDrugs Team